Bo Zhang

Dr. Bo Zhang

Department of Cardiology, First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, China
orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 February 2025 in Basic Research in Cardiology
Verified
Journal Article
Closed access
PDF file
ZLZi-Zhuo Li
Zi-Zhuo Li
LGLei Guo
Lei Guo
YAYan-Liang An
Yan-Liang An
WYWei-Jia Yu
Wei-Jia Yu
DSDing-Yu Shi
Ding-Yu Shi
BZBo Zhang
Bo Zhang

20 May 2015 in Frontiers in Physiology
Verified
Journal Article
Open access
PDF file
YLYonggang Liu
Yonggang Liu
JGJamie M. Goodson
Jamie M. Goodson
BZBo Zhang
Bo Zhang
Michael T. ChinMichael T. Chin
Michael T. Chin
EExposure to air pollution has long been known to trigger cardiovascular events, primarily through activation of local and systemic inflammatory pathways that affect the vasculature. Detrimental effects of air pollution exposure on heart failure and cardiac remodeling have also been described in human populations. Recent studies in both human subjects and animal models have provided insights into the basic physiological, cellular and molecular mechanisms that play a role in adverse cardiac remodeling. This review will give a brief overview of the relationship between air pollution and cardiovascular disease, describe the clinical effects of air pollution exposure on cardiac remodeling, describe the basic mechanisms that affect remodeling as described in human and animal systems and will discuss future areas of investigation.

1 July 2025 in Journal of the American Heart Association
Verified
Journal Article
Open access
PFPeng Fu
Peng Fu
XHXiao Han
Xiao Han
QLQiuyue Lin
Qiuyue Lin
NWNing Wang
Ning Wang
FSFang‐Fang Sun
Fang‐Fang Sun
BZBo Zhang
Bo Zhang
Background: Myocardial ischemia/reperfusion (I/R) injury is a leading cause of myocardial dysfunction and is associated with inflammation, apoptosis, and fibrosis. The integrin subunit ITGAM (also known as CD11b) mainly mediates leukocyte infiltration in the inflammatory process. However, the importance of CD11b in the development of myocardial I/R injury is unclear. The goal of this study is to investigate the role of CD11b + immune cells, particularly neutrophils and macrophages, in mediating myocardial I/R injury and to evaluate the therapeutic potential of CD11b inhibition. Methods: Wild‐type mice were administered an anti‐CD11b neutralizing antibody before myocardial I/R surgery. Echocardiography and histological staining were used to evaluate cardiac function and injury, respectively. Inflammatory cells were analyzed by flow cytometry in mice and patients with myocardial infarction who underwent percutaneous coronary intervention. Activated fibroblasts from patients with myocardial infarction were detected by positron emission tomography/computed tomography with a [(18)F]‐labeled fibroblast activation protein inhibitor. Results: Our results indicated that CD11b expression and the number of CD45 + CD11b + bone marrow mononuclear cells were dramatically increased in the heart tissues of I/R‐treated mice. Moreover, compared with immunoglobulin G treatment, the pharmacological inhibition of CD11b in mice greatly alleviated cardiac dysfunction, infarct size, myocyte apoptosis, CD11b + neutrophils and macrophage infiltration, cardiac fibrosis and fibroblast activation, accompanied by the inhibition of multiple signaling pathways (Bax, caspase‐3, nuclear factor‐κB, and transforming growth factor‐β/Smad2/3) 3 days after I/R surgery. In addition, the numbers of CD15 + CD11b + neutrophils and CD14 + CD11b + monocytes and the levels of inflammatory cytokines (intercellular adhesion molecule ‐1, vascular adhesion molecule ‐1, interleukin‐1β, and interleukin‐6) as well as the levels of fibroblast activation protein inhibitor in patients with myocardial infarction were also significantly greater than those in normal controls. Conclusions: Our data demonstrate that CD11b plays an important role in promoting myocardial I/R injury through multiple signaling pathways and that targeting CD11b may represent a promising option for treating heart I/R injury.

10 December 2020 in Acta Pharmacologica Sinica
Verified
Journal Article
Closed access
PDF file
ZDZhi-Chao Dong
Zhi-Chao Dong
MWMing-Ming Wu
Ming-Ming Wu
YZYun-Long Zhang
Yun-Long Zhang
QWQiu-Shi Wang
Qiu-Shi Wang
CLChen Liang
Chen Liang
ZZZhi-Ren Zhang
Zhi-Ren Zhang

1 January 2022 in Oxidative Medicine and Cellular Longevity
Verified
Journal Article
Open access
PDF file
YZYUNLONG ZHANG
YUNLONG ZHANG
BZBo Zhang
Bo Zhang
XHXiao Han
Xiao Han
BZBo Zhang
Bo Zhang
HLHuihua Li
Huihua Li
Myocardial ischemia/reperfusion injury (I/RI) is closely associated with energy substrate metabolism. Fibronectin 1 (Fn1) was markedly elevated in the heart of I/R pigs and ischemic patients, but its role in myocardial I/RI is controversial and the precise mechanism involved remains elusive. Herein, we tested whether blockage of Fn1 with its inhibitor (fibronectin tetrapeptide, RGDS) would alleviate myocardial I/RI. Wild‐type (WT) mice were administered with RGDS once 3 h before I/R operation and once at 24 or 48 h postreperfusion, and sacrificed at 24 or 72 h post‐I/R, respectively. Cardiac function was evaluated by echocardiography. Myocardial infarction size, apoptosis, fibrosis, and inflammation were examined via histological staining. Uptake of glucose and fatty acids were detected by positron emission tomography (PET) and computer tomography (CT) with [18F]‐2‐fluoro‐2‐deoxy‐D‐glucose (FDG) and [18F]‐fluoro‐6‐thia‐heptadecanoic acid (FTHA), respectively. Our results showed that administration of RGDS to mice remarkably limited the I/R‐induced myocardial infarct size, myocyte apoptosis, inflammation, oxidative stress, and fibrosis and improved cardiac contractile dysfunction. These protective effects were associated with upregulation of the AMP/ATP ratio and the activation of LKB1‐AMPK signaling, which subsequently increased AS160‐GLUT4‐mediated glucose and fatty acid uptake, improved mitochondrial dynamic imbalance, and inactivated TGF‐β and NF‐κB signals in the I/R heart. In conclusion, the current study identified that blocking Fn1 protects against myocardial I/RI likely through activating the LKB1‐AMPK‐dependent signals and highlights that inhibition of Fn1 may be a novel therapeutic option for treating ischemic heart diseases.

26 January 2021 in Frontiers in Cell and Developmental Biology
Verified
Journal Article
Open access
SLShuang Liu
Shuang Liu
WSWen-Chang Sun
Wen-Chang Sun
YZYun-Long Zhang
Yun-Long Zhang
QLQiu-Yue Lin
Qiu-Yue Lin
JLJia-Wei Liao
Jia-Wei Liao
BZBo Zhang
Bo Zhang
Pressure overload-induced hypertrophic remodeling is a critical pathological process leading to heart failure (HF). Suppressor of cytokine signaling-3 (SOCS3) has been demonstrated to protect against cardiac hypertrophy and dysfunction, but its mechanisms are largely unknown. Using primary cardiomyocytes and cardiac-specific SOCS3 knockout (SOCS3cko) or overexpression mice, we demonstrated that modulation of SOCS3 level influenced cardiomyocyte hypertrophy, apoptosis and cardiac dysfunction induced by hypertrophic stimuli. We found that glucose regulatory protein 78 (GRP78) was a direct target of SOCS3, and that overexpression of SOCS3 inhibited cardiomyocyte hypertrophy and apoptosis through promoting proteasomal degradation of GRP78, thereby inhibiting activation of endoplasmic reticulum (ER) stress and mitophagy in the heart. Thus, our results uncover SOCS3-GRP78-mediated ER stress as a novel mechanism in the transition from cardiac hypertrophy to HF induced by sustained pressure overload, and suggest that modulating this pathway may provide a new therapeutic approach for hypertrophic heart diseases.